Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
17 nov. 2023 16h30 HE
|
Passage Bio
PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
13 nov. 2023 07h00 HE
|
Passage Bio
On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with...
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
30 oct. 2023 07h00 HE
|
Passage Bio
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 oct. 2023 16h30 HE
|
Passage Bio
PHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
25 sept. 2023 07h00 HE
|
Passage Bio
PHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
07 août 2023 07h15 HE
|
Passage Bio
Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF...
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
07 août 2023 07h00 HE
|
Passage Bio
Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF...
Passage Bio to Participate in Upcoming Investor Conferences
01 août 2023 07h00 HE
|
Passage Bio
PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
31 juil. 2023 07h00 HE
|
Passage Bio
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
05 juin 2023 07h00 HE
|
Passage Bio
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system...